Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design

被引：0
|
作者：
Valvanera Vozmediano
Ander Sologuren
John C. Lukas
Nerea Leal
Mónica Rodriguez
机构：
[1] Drug Modeling & Consulting,
[2] Dynakin,undefined
[3] SL,undefined
[4] Clinical Research Department,undefined
[5] FAES FARMA,undefined
[6] S.A.,undefined
来源：
Pharmaceutical Research | 2017年 / 34卷
关键词：
bilastine; knowledge integration; Ontogenic model; pediatric drug development; quantitative pharmacology; semiphysiological;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2720 / 2734
页数：14
相关论文
共 50 条
  • [31] Model-informed drug development for immuno-oncology agonistic anti-GITR antibody GWN323: Dose selection based on MABEL and biologically active dose
    Ji, Yan
    Knee, Deborah
    Chen, Xinhui
    Dang, Anhthu
    Mataraza, Jennifer
    Wolf, Babette
    Sy, Sherwin K. B.
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (09): : 2218 - 2229
  • [32] Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model-Informed Dose Selection in Oncology First-in-Human Study: A Case of Roblitinib (FGF401)
    Wilbaux, Melanie
    Yang, Shu
    Jullion, Astrid
    Demanse, David
    Porta, Diana Graus
    Myers, Andrea
    Meille, Christophe
    Gu, Yi
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1329 - 1339
  • [33] Right Dose, Right Now: Development of AutoKinetics for Real Time Model Informed Precision Antibiotic Dosing Decision Support at the Bedside of Critically Ill Patients
    Roggeveen, Luca F.
    Guo, Tingjie
    Driessen, Ronald H.
    Fleuren, Lucas M.
    Thoral, Patrick
    van der Voort, Peter H. J.
    Girbes, Armand R. J.
    Bosman, Rob J.
    Elbers, Paul
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [34] Model-based dose selection to inform translational clinical oncology development of WNT974, a first-in-class Porcupine inhibitor
    Ji, Yan
    Huang, Pai-Hsi
    Woolfenden, Steve
    Myers, Andrea
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (07): : 1713 - 1722
  • [35] Optimization of the dose and schedule of an HDM2 inhibitor NVP-HDM201 in a first-in-human Phase I study using a mechanism-based PK/PD model
    Meille, Christophe
    Guerreiro, Nelson
    Jullion, Astrid
    Bauer, Sebastian
    Chatterjee, Manik
    de Vos, Filip
    Lin, Chia-Chi
    Rodriguez, Cristina Suarez
    Tai, David
    Cassier, Philippe
    Yamamoto, Noboru
    de Weger, Vincent A.
    Klopfenstein, Matthieu
    Mariconti, Luisa
    Kuriakose, Emil T.
    Hyman, David M.
    [J]. CANCER RESEARCH, 2017, 77
  • [36] Tofacitinib Dose Selection by Extrapolation of Efficacy from Adult RA to Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Optimal Design to Select PK Sampling Times for a Phase 3 (P3) Study in Children
    Hazra, Anasuya
    Vong, Camille
    Stock, Thomas
    Krishnaswami, Sriram
    Peterson, Mark
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S50 - S50
  • [37] Requirement-driven model-based development methodology applied to the design of a real-time MEG data processing unit
    Chen, Tao
    Schiek, Michael
    Dammers, Juergen
    Shah, N. Jon
    van Waasen, Stefan
    [J]. SOFTWARE AND SYSTEMS MODELING, 2020, 19 (06): : 1567 - 1587
  • [38] Target-Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model-Informed Dose Selection for the First-in-Human Study of AVB-S6-500
    Bonifacio, Laura
    Dodds, Michael
    Prohaska, David
    Moss, Aaron
    Giaccia, Amato
    Tabibiazar, Ray
    McIntyre, Gail
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 204 - 211
  • [39] Requirement-driven model-based development methodology applied to the design of a real-time MEG data processing unit
    Tao Chen
    Michael Schiek
    Jürgen Dammers
    N. Jon Shah
    Stefan van Waasen
    [J]. Software and Systems Modeling, 2020, 19 : 1567 - 1587
  • [40] A case-study of model-informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II
    Knochel, Jane
    Nilsson, Catarina
    Carlsson, Bjorn
    Wernevik, Linda
    Hofherr, Alexis
    Gennemark, Peter
    Jansson-Lofmark, Rasmus
    Isaksson, Rikard
    Ryden-Bergsten, Tina
    Hamren, Bengt
    Rekic, Dinko
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (12): : 1569 - 1577
12345